Academic Journals Database
Disseminating quality controlled scientific knowledge

Molecular targeted therapies in metastatic melanoma

Author(s): Chakraborty R | Wiel | CN | Comfere NI

Journal: Pharmacogenomics and Personalized Medicine
ISSN 1178-7066

Volume: 2013;
Issue: default;
Start page: 49;
Date: 2013;
Original page

Rima Chakraborty,1 Carilyn N Wieland,2 Nneka I Comfere2 1University of Missouri-Kansas City Medical School, Kansas City, MO, 2Departments of Dermatology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA Abstract: The advent of personalized medicine has ushered in a new era for cancer therapy with a significant impact on the management of advanced melanoma. Molecular targeted therapies have shown promise in the management of various malignancies, including melanoma, with lower toxicity profiles and better overall survival as compared with conventional therapy. The discovery of BRAF mutations in melanoma led to the development of BRAF inhibitors for the treatment of advanced melanoma. However, growing concerns over drug resistance to molecular targeted therapies including BRAF inhibitors, have spurred efforts to elucidate additional molecular targets for the treatment of advanced melanoma. In this review, we discuss the known molecular aberrations in melanoma, current and novel targeted approaches in its treatment, and drug resistance patterns. Keywords: BRAF inhibitors, metastatic melanoma, personalized medicine
RPA Switzerland

RPA Switzerland

Robotic process automation


Tango Jona
Tangokurs Rapperswil-Jona